INTANGIBLE ASSETS - Narrative (Details) - USD ($) |
3 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|
Apr. 01, 2023 |
Oct. 01, 2022 |
Apr. 01, 2023 |
Apr. 02, 2022 |
Apr. 03, 2021 |
|
| Amortizable intangible assets: | Ìý | Ìý | Ìý | Ìý | Ìý |
| Impairment of indefinite lived intangible assets | Ìý | Ìý | Ìý | $ 0 | $ 20,400,000 |
| Amortization of intangible assets | Ìý | Ìý | $ 14,100,000 | $ 15,600,000 | $ 17,500,000 |
| Estimated amortization expense, 2024 | $ 13,600,000 | Ìý | 13,600,000 | Ìý | Ìý |
| Estimated amortization expense, 2025 | 13,000,000 | Ìý | 13,000,000 | Ìý | Ìý |
| Estimated amortization expense, 2026 | 12,100,000 | Ìý | 12,100,000 | Ìý | Ìý |
| Estimated amortization expense, 2027 | 11,600,000 | Ìý | 11,600,000 | Ìý | Ìý |
| Estimated amortization expense, 2028 | 10,700,000 | Ìý | 10,700,000 | Ìý | Ìý |
| Supreme | Ìý | Ìý | Ìý | Ìý | Ìý |
| Amortizable intangible assets: | Ìý | Ìý | Ìý | Ìý | Ìý |
| Impairment of indefinite lived intangible assets | $ 148,000,000 | $ 192,900,000 | $ 340,900,000 | Ìý | Ìý |
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|